Frontlight ResearchEarly access
Active, not recruitingNo phase
Post Market Clinical Follow-up of EUROSTEM Femoral Stem
Key facts
- Who runs it
- EUROS
- Where
- France9 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 131 people, planned
- Started
- 21 May 2021
- Expected to end
- 6 Nov 2032
- Type of study
- Observational
- Treatments tested
- hip arthroplasty
- Record updated
- 20 February 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patient who received EUROSTEM
- Patient informed of its participation to the study
- Patient aged over 18 to date of surgery
Who cannot take part
- Patient presenting a contraindication to EUROSTEM implantation
- Patient who refused to participate to the study
- Vulnerable subjects
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
EUROSSTEM is intended for use in primary and revision total hip replacement surgery.
Read full original descriptionShow less
Hip replacement is intended to provide increased patient mobility and reduce pain by replacing the damages hip joint articulation in patients where there is evidence of sufficient sound bone to seat and support the components.
As part of post market vigilance, EUROS will collect data on EUROSTEM performances and safety
The group in the trial
- EUROSTEM femoral stem
All patients who received EUROSTEM femoral stem whatever the version (cemented or cementless)
Treatment: hip arthroplasty
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 20 February 2024